MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics Interest Expense 2011-2026 | FLGT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 561 K | 320 K | 887 K | - | 20 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 887 K | 20 K | 447 K |
Quarterly Interest Expense Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5 K | 46 K | 68 K | - | 544 K | 11 K | -9 K | - | 244 K | 136 K | 200 K | - | 105 K | 50 K | 29 K | -35 K | 30 K | 29 K | 29 K | 589 K | - | - | 241 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 589 K | -35 K | 128 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.19 | 0.5 % | $ 174 M |  China |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 117.7 | 2.28 % | $ 35.8 B |  USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.76 | 4.42 % | $ 893 M | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.2 | -4.35 % | $ 9.73 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.43 | 4.38 % | $ 1.9 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.18 | 0.22 % | $ 644 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 177.87 | 1.25 % | $ 8.82 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 498.89 | 1.09 % | $ 14.4 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 194.47 | 2.58 % | $ 139 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.59 | 5.4 % | $ 425 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.95 | 3.38 % | $ 1.02 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 126.18 | 4.34 % | $ 20.1 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 80.98 | 3.03 % | $ 10.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.69 | 0.15 % | $ 279 M | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.77 | 2.79 % | $ 89.9 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.07 | -3.05 % | $ 4.75 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.52 | 0.76 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 110.04 | 3.02 % | $ 9.08 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.64 | 0.01 % | $ 2.68 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 263.77 | 1.09 % | $ 21.9 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 199.3 | 3.25 % | $ 19.6 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 119.06 | 1.64 % | $ 5.57 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 80.85 | 0.32 % | $ 5.46 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neuronetics
STIM
|
716 K | $ 1.37 | 1.11 % | $ 90.4 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 190.84 | -0.36 % | $ 21.2 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.32 | -1.01 % | $ 2.02 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 4.97 | 0.61 % | $ 3.91 M | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |